Sarepta plans regulatory submissions for Duchenne drugs

Sarepta Therapeutics is preparing to submit regulatory filings for two of its Duchenne muscular dystrophy drugs by April 2026. This timeline indicates significant progress in the development and clinical testing phases for these treatments. The company is focused on bringing these potentially life-changing therapies to patients who currently have limited options. Successful regulatory submissions and subsequent approvals could mark a major milestone for Sarepta and offer new hope for individuals affected by this rare genetic disorder.